Mandatory CSP Appointment for DIFC Prescribed Companies (SPVs):
What You Need to Know
The DIFC Prescribed Company regime has entered a new chapter.
Since 24 July 2026, the DIFC Prescribed Company Regulations 2026 have made Prescribed Companies, commonly referred to as Special Purpose Vehicles or SPVs, more accessible to individuals, families, investors and corporate groups worldwide.
While the revised regime creates new opportunities for international structuring, it also introduces important governance, recordkeeping and compliance responsibilities. One of the most significant changes is the requirement for every Prescribed Company to appoint and continuously maintain an eligible Corporate Service Provider regulated by the Dubai Financial Services Authority, unless the company qualifies as an Exempt PC.
Existing owners and prospective applicants should therefore understand how the revised regime affects them, whether an exemption may apply and what action must be taken to remain compliant.
A more accessible structure
Under the previous regime, applicants were required to satisfy specific eligibility conditions relating to their status, purpose or connection to the DIFC or the Gulf Cooperation Council.
These restrictions have now been removed. As a result, individuals and companies based in most parts of the world may generally establish a DIFC Prescribed Company.
This broader accessibility may be particularly attractive to international investors, family offices and corporate groups seeking a recognised and flexible structure through which to hold investments, shares or other eligible assets.
However, greater accessibility does not change the fundamental nature of a Prescribed Company. It remains primarily a passive holding vehicle and is not intended to operate as an active commercial business.
Understanding the purpose of a Prescribed Company
Depending on its licence and intended purpose, a Prescribed Company may be used to hold shares in in subsidiaries or other companies, investments, financing rights and assets forming part of a family wealth or succession-planning arrangement.
It may appoint directors and engage Corporate Service Providers, legal advisers, accountants and other professionals to assist with the administration of its affairs.
A Prescribed Company cannot, however, ordinarily conduct an active commercial business, employ staff, sponsor employment or residence visas, or provide regulated financial services without the appropriate licence or regulatory approval.
The proposed purpose and activities of the company should therefore be carefully considered from the outset. A Prescribed Company can be an effective and flexible structuring vehicle, but only where it is appropriate for the intended arrangement.
The new requirement to appoint a Corporate Service Provider
One of the most important changes introduced by the revised Regulations is the requirement for every Prescribed Company to appoint and continuously maintain an eligible Corporate Service Provider regulated by the DFSA, unless the company qualifies as an Exempt PC.
An exemption may be available where the company’s Controller is a DIFC Registered Person, an Authorised Firm, a Government Entity or a Publicly Listed Entity.
Exempt status should not be assumed. The Prescribed Company must be able to demonstrate and document the basis upon which it qualifies for an exemption. Its eligibility should also be reassessed whenever there is a change in ownership, control or group structure.
Companies controlled through a Foundation or a Prescribed Variable Capital Company may require particular consideration, as their eligibility for an exemption could be affected under the revised Regulations.
A closer relationship between the company and its CSP
The role of the Corporate Service Provider has expanded considerably under the new regime.
The appointed CSP will act as the Prescribed Company’s principal administrative and compliance contact with the DIFC Registrar of Companies. Its role may include managing regulatory applications and notifications, facilitating annual licence renewals, maintaining corporate records, coordinating regulatory filings and responding to requests from the relevant authorities.
The CSP will also help ensure that information relating to the company’s directors, shareholders, Controllers and beneficial owners remains complete, accurate and up to date.
Subject to the CSP’s agreement and the applicable DIFC requirements, a Prescribed Company may also have the option of using the CSP’s office address as its registered office address. This may provide the company with an established address in the DIFC through which official correspondence and regulatory communications can be received and appropriately managed.
The relationship between a Prescribed Company and its CSP must therefore remain active throughout the year. It should not be limited to communications taking place only when the annual licence renewal becomes due.
Maintaining accurate and up-to-date records
For the CSP to perform its role effectively, the Prescribed Company must provide all necessary information and supporting documentation in a timely manner.
Changes involving directors, shareholders, authorised signatories, Controllers or beneficial owners should be reported promptly. The same applies to share transfers, new share issuances, corporate approvals, changes in ownership or control, and any other matter requiring a regulatory filing or notification.
The company should also maintain appropriate accounting records and clear information concerning its assets, activities and underlying arrangements.
Waiting until the annual renewal to disclose significant changes could place both the company and its CSP in a difficult regulatory position. A failure to provide the required information or supporting documents may result in an administrative fine of up to USD 100,000.
Greater attention to ownership and financial crime risks
Opening the Prescribed Company regime to a broader international audience may result in more complex ownership structures and a wider range of geographical and financial crime risks.
The individuals who ultimately own or control the company must be clearly identified and understood. The company’s purpose and the commercial rationale supporting the structure should also be properly documented.
Depending on the circumstances, the due diligence process may involve verifying the source of wealth and source of funds, conducting sanctions and politically exposed person screening, reviewing adverse media and assessing the risks associated with relevant countries, industries and activities.
These checks should not be treated as a one-time exercise completed during incorporation. They should be reviewed periodically and whenever there is a material change in the company’s ownership, control, activities or circumstances.
An important deadline for existing companies
Non-exempt Prescribed Companies incorporated before 24 July 2026 must appoint an eligible CSP within six months of the new Regulations coming into force.
The transitional deadline is 24 January 2027.
Existing owners should begin reviewing their arrangements as early as possible. Additional time may be required to determine whether an exemption applies, confirm whether the current service provider has the necessary regulatory status, complete or update due diligence and reconcile the company’s corporate and beneficial ownership records.
An early review may also identify missing documents, outdated information or outstanding regulatory filings that should be addressed before the deadline.
The consequences of non-compliance
A Prescribed Company that fails to appoint and continuously maintain an eligible CSP when required may face a fine of up to USD 20,000.
More serious contraventions, including a failure to provide the CSP with the required information and supporting documents, may result in a fine of up to USD 100,000.
The company may also risk losing its prescribed status and being treated as an ordinary DIFC company. This could result in higher annual licence fees, physical office requirements, increased administration costs and additional governance obligations.
For a company established specifically to support an investment, holding or succession-planning arrangement, these consequences could cause significant and unnecessary disruption.
What should existing owners do now?
The first step is to determine whether the Prescribed Company is exempt or required to appoint an eligible CSP. Where an exemption is claimed, the basis for that exemption should be clearly documented and supported by appropriate evidence.
Owners should also confirm whether their existing service provider has the necessary regulatory status and review the company’s corporate, accounting and beneficial ownership records. Any outstanding regulatory filings or inconsistencies should be identified and addressed.
It is equally important to confirm that the company’s current activities remain within the scope of its licence and that its AML/CFT/CPF and sanctions risk assessments remain accurate and appropriate.
Where compliance gaps are identified, they should be addressed through a clear and practical remediation plan well before the January 2027 deadline.
How JurisTax MENA can assist
JurisTax MENA can help clients understand how the revised Regulations affect an existing or proposed DIFC Prescribed Company.
Our team can assess whether a Prescribed Company is suitable for the intended structure, review an existing company’s position under the new regime and help determine whether it is exempt or non-exempt.
We can also coordinate CSP appointment requirements, review ownership and beneficial ownership information, help address incomplete corporate records and assess whether the company’s activities remain consistent with its licence.
Where necessary, we can support the review of AML/CFT/CPF and sanctions risks, strengthen governance procedures and establish a practical compliance calendar for ongoing obligations.
The revised Regulations have made DIFC Prescribed Companies more accessible to investors, families and corporate groups worldwide. However, the benefits of the structure will depend on how carefully the company is established, administered and monitored.
Owners of existing Prescribed Companies should act early to determine whether the mandatory CSP requirement applies to them and ensure that all necessary arrangements are completed before the transitional deadline of 24 January 2027.